All HHS Contracts — May 21, 2026
This digest covers $685.3 million in HHS contract obligations from May 21, 2026, with zero defense exposure, underscoring a pure civilian healthcare IT and life sciences R&D theme. The dominant signal is a $432.5 million Leidos Biomedical Research GOCO facility contract with NIH, representing 63% of total value and providing stable, multi-year cost-plus revenue. A $95.1 million Peraton fraud prevention contract with CMS adds a high-conviction, politically supported IT growth play. Key risks include a $80.7 million SOFTRAMS HUBZone contract expiring August 2024 (revenue cliff) and a $77.1 million Chimerix BARDA contract that was largely unfunded, highlighting execution risk. The highest-conviction signal is Peraton's CMS Fraud Prevention System 2 award, given CMS's sustained focus on fraud reduction and the time-and-materials pricing flexibility.